| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Angiotensin I | 59 | 2021 | 239 | 8.120 |
Why?
|
| Peptide Fragments | 62 | 2021 | 430 | 8.010 |
Why?
|
| Peptidyl-Dipeptidase A | 46 | 2021 | 132 | 7.360 |
Why?
|
| Renin-Angiotensin System | 48 | 2021 | 178 | 7.330 |
Why?
|
| Kidney | 36 | 2019 | 528 | 5.860 |
Why?
|
| Angiotensin II | 48 | 2021 | 244 | 4.940 |
Why?
|
| Hypertension | 42 | 2019 | 1024 | 4.450 |
Why?
|
| Renin | 33 | 2019 | 109 | 3.960 |
Why?
|
| Receptors, G-Protein-Coupled | 16 | 2019 | 91 | 3.420 |
Why?
|
| Blood Pressure | 55 | 2019 | 901 | 3.010 |
Why?
|
| Animals | 118 | 2021 | 8578 | 2.570 |
Why?
|
| Kidney Tubules, Proximal | 9 | 2017 | 40 | 2.280 |
Why?
|
| Angiotensins | 16 | 2018 | 42 | 2.240 |
Why?
|
| Prenatal Exposure Delayed Effects | 18 | 2019 | 95 | 2.140 |
Why?
|
| Betamethasone | 17 | 2019 | 53 | 2.120 |
Why?
|
| Rats | 60 | 2020 | 1946 | 1.960 |
Why?
|
| Angiotensinogen | 16 | 2016 | 59 | 1.850 |
Why?
|
| Nitric Oxide | 11 | 2018 | 124 | 1.730 |
Why?
|
| Receptor, Angiotensin, Type 1 | 14 | 2017 | 64 | 1.690 |
Why?
|
| Sheep | 26 | 2018 | 233 | 1.630 |
Why?
|
| Rats, Inbred Lew | 26 | 2020 | 123 | 1.570 |
Why?
|
| Estrogens | 7 | 2014 | 210 | 1.510 |
Why?
|
| Sodium Chloride, Dietary | 8 | 2016 | 28 | 1.480 |
Why?
|
| Glucocorticoids | 14 | 2019 | 154 | 1.470 |
Why?
|
| Estradiol | 7 | 2013 | 156 | 1.420 |
Why?
|
| Cell Nucleus | 5 | 2014 | 119 | 1.380 |
Why?
|
| Mitochondria | 5 | 2019 | 219 | 1.330 |
Why?
|
| Receptors, Angiotensin | 9 | 2011 | 61 | 1.330 |
Why?
|
| Ovariectomy | 11 | 2013 | 204 | 1.320 |
Why?
|
| Baroreflex | 13 | 2019 | 86 | 1.310 |
Why?
|
| Proto-Oncogene Proteins | 7 | 2019 | 90 | 1.160 |
Why?
|
| Cyclopentanes | 7 | 2016 | 17 | 1.130 |
Why?
|
| Quinolines | 7 | 2016 | 29 | 1.130 |
Why?
|
| Oxidative Stress | 9 | 2019 | 265 | 1.100 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 15 | 2012 | 138 | 1.060 |
Why?
|
| Vasodilation | 7 | 2017 | 96 | 1.040 |
Why?
|
| Kidney Cortex | 6 | 2015 | 25 | 1.020 |
Why?
|
| Signal Transduction | 10 | 2019 | 771 | 1.010 |
Why?
|
| Myocardium | 13 | 2014 | 199 | 0.950 |
Why?
|
| Female | 63 | 2021 | 21531 | 0.940 |
Why?
|
| Peptide Hydrolases | 3 | 2015 | 19 | 0.890 |
Why?
|
| Reactive Oxygen Species | 8 | 2019 | 174 | 0.870 |
Why?
|
| Male | 68 | 2020 | 20739 | 0.840 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 13 | 2019 | 70 | 0.830 |
Why?
|
| Pregnancy | 28 | 2019 | 1069 | 0.810 |
Why?
|
| Medulla Oblongata | 7 | 2019 | 51 | 0.800 |
Why?
|
| Epithelial Cells | 5 | 2016 | 148 | 0.790 |
Why?
|
| Nitric Oxide Synthase Type III | 4 | 2018 | 37 | 0.780 |
Why?
|
| Carboxypeptidases | 8 | 2005 | 21 | 0.770 |
Why?
|
| Humans | 45 | 2021 | 34562 | 0.740 |
Why?
|
| Mesenteric Arteries | 5 | 2013 | 21 | 0.730 |
Why?
|
| Gene Expression Regulation | 10 | 2012 | 526 | 0.730 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2021 | 165 | 0.730 |
Why?
|
| Radioimmunoassay | 3 | 2021 | 28 | 0.690 |
Why?
|
| Chromatography, High Pressure Liquid | 3 | 2017 | 97 | 0.690 |
Why?
|
| Imidazoles | 11 | 2017 | 99 | 0.690 |
Why?
|
| Fetal Development | 4 | 2018 | 27 | 0.680 |
Why?
|
| Fetus | 2 | 2019 | 91 | 0.630 |
Why?
|
| Aging | 8 | 2013 | 1010 | 0.630 |
Why?
|
| Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 2 | 2017 | 6 | 0.620 |
Why?
|
| Proteinuria | 8 | 2014 | 55 | 0.590 |
Why?
|
| Muscle, Smooth, Vascular | 3 | 2013 | 62 | 0.570 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 98 | 0.560 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 103 | 0.560 |
Why?
|
| Tetrazoles | 10 | 2019 | 62 | 0.560 |
Why?
|
| Losartan | 10 | 2017 | 68 | 0.550 |
Why?
|
| Blotting, Western | 9 | 2017 | 328 | 0.540 |
Why?
|
| Diastole | 5 | 2014 | 100 | 0.530 |
Why?
|
| Mice | 21 | 2017 | 2720 | 0.530 |
Why?
|
| Renal Artery | 2 | 2017 | 50 | 0.520 |
Why?
|
| Immunohistochemistry | 13 | 2013 | 600 | 0.520 |
Why?
|
| Receptors, Bradykinin | 1 | 2017 | 2 | 0.520 |
Why?
|
| Molecular Probe Techniques | 1 | 2017 | 4 | 0.510 |
Why?
|
| Premature Birth | 4 | 2019 | 75 | 0.500 |
Why?
|
| Amiloride | 1 | 2016 | 5 | 0.500 |
Why?
|
| Sodium | 8 | 2017 | 42 | 0.490 |
Why?
|
| Cardiovascular System | 2 | 2019 | 51 | 0.490 |
Why?
|
| Disease Models, Animal | 20 | 2019 | 1128 | 0.490 |
Why?
|
| Conjunctival Diseases | 1 | 2016 | 4 | 0.480 |
Why?
|
| Lisinopril | 6 | 2012 | 26 | 0.480 |
Why?
|
| Eye Injuries | 1 | 2016 | 16 | 0.470 |
Why?
|
| Ventricular Dysfunction, Left | 4 | 2014 | 184 | 0.460 |
Why?
|
| Rats, Transgenic | 14 | 2019 | 48 | 0.460 |
Why?
|
| Ornithine | 2 | 2012 | 4 | 0.460 |
Why?
|
| Neprilysin | 7 | 2013 | 31 | 0.460 |
Why?
|
| Heart | 7 | 2019 | 191 | 0.450 |
Why?
|
| Antihypertensive Agents | 8 | 2019 | 379 | 0.440 |
Why?
|
| Cardiovascular Diseases | 2 | 2020 | 1209 | 0.440 |
Why?
|
| Diabetes Mellitus, Experimental | 3 | 2012 | 71 | 0.440 |
Why?
|
| Nitric Oxide Synthase Type I | 2 | 2012 | 18 | 0.430 |
Why?
|
| Nitric Oxide Synthase | 4 | 2014 | 43 | 0.430 |
Why?
|
| Sex Factors | 11 | 2019 | 707 | 0.430 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2014 | 38 | 0.430 |
Why?
|
| RNA, Messenger | 14 | 2015 | 545 | 0.420 |
Why?
|
| Diabetic Nephropathies | 2 | 2013 | 228 | 0.410 |
Why?
|
| Choroid Plexus | 1 | 2013 | 3 | 0.410 |
Why?
|
| Cyclic AMP | 1 | 2013 | 56 | 0.400 |
Why?
|
| Brain | 8 | 2019 | 1031 | 0.390 |
Why?
|
| Receptors, Estrogen | 2 | 2014 | 117 | 0.370 |
Why?
|
| Kidney Glomerulus | 1 | 2012 | 30 | 0.360 |
Why?
|
| Hypertension, Renal | 3 | 2007 | 29 | 0.360 |
Why?
|
| Sex Characteristics | 4 | 2015 | 182 | 0.350 |
Why?
|
| Cell Line | 5 | 2016 | 476 | 0.350 |
Why?
|
| Gene Expression Regulation, Enzymologic | 5 | 2011 | 85 | 0.350 |
Why?
|
| Receptor, Angiotensin, Type 2 | 2 | 2009 | 22 | 0.340 |
Why?
|
| Kidney Diseases | 3 | 2012 | 249 | 0.340 |
Why?
|
| Pyridines | 7 | 2017 | 87 | 0.340 |
Why?
|
| NG-Nitroarginine Methyl Ester | 4 | 2017 | 19 | 0.340 |
Why?
|
| Vagus Nerve | 3 | 2019 | 30 | 0.330 |
Why?
|
| Heart Rate | 13 | 2019 | 372 | 0.330 |
Why?
|
| Scleroderma, Systemic | 1 | 2010 | 8 | 0.330 |
Why?
|
| Down-Regulation | 4 | 2015 | 145 | 0.320 |
Why?
|
| Autoantibodies | 1 | 2010 | 52 | 0.320 |
Why?
|
| Benzimidazoles | 6 | 2019 | 31 | 0.310 |
Why?
|
| Leucine | 5 | 2010 | 24 | 0.310 |
Why?
|
| Dinoprost | 2 | 2014 | 11 | 0.310 |
Why?
|
| Enzyme Inhibitors | 4 | 2011 | 185 | 0.290 |
Why?
|
| Time Factors | 11 | 2016 | 2353 | 0.280 |
Why?
|
| Protease Inhibitors | 3 | 2014 | 15 | 0.280 |
Why?
|
| Pre-Eclampsia | 3 | 2015 | 67 | 0.280 |
Why?
|
| Carboxypeptidases A | 1 | 2008 | 1 | 0.280 |
Why?
|
| Chromatography, Agarose | 2 | 2021 | 5 | 0.280 |
Why?
|
| Bradykinin | 3 | 2017 | 12 | 0.260 |
Why?
|
| Sympathetic Nervous System | 3 | 2019 | 34 | 0.250 |
Why?
|
| Acute Radiation Syndrome | 2 | 2016 | 4 | 0.250 |
Why?
|
| Solitary Nucleus | 4 | 2011 | 34 | 0.250 |
Why?
|
| Oligopeptides | 3 | 2016 | 55 | 0.250 |
Why?
|
| Animals, Congenic | 6 | 2016 | 14 | 0.240 |
Why?
|
| Prenatal Nutritional Physiological Phenomena | 1 | 2005 | 5 | 0.230 |
Why?
|
| Substrate Specificity | 3 | 2014 | 91 | 0.230 |
Why?
|
| Hemodynamics | 3 | 2019 | 168 | 0.230 |
Why?
|
| Fibrosis | 4 | 2010 | 131 | 0.220 |
Why?
|
| Cardiomegaly | 4 | 2010 | 31 | 0.220 |
Why?
|
| Sheep, Domestic | 4 | 2019 | 19 | 0.220 |
Why?
|
| Aldosterone | 4 | 2014 | 27 | 0.220 |
Why?
|
| Age Factors | 6 | 2019 | 1262 | 0.210 |
Why?
|
| Placenta | 2 | 2019 | 76 | 0.210 |
Why?
|
| Postural Balance | 1 | 2016 | 152 | 0.210 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2015 | 111 | 0.210 |
Why?
|
| Infant, Premature | 3 | 2018 | 80 | 0.200 |
Why?
|
| Pesticides | 1 | 2016 | 201 | 0.200 |
Why?
|
| Occupational Exposure | 1 | 2016 | 237 | 0.200 |
Why?
|
| Up-Regulation | 4 | 2013 | 204 | 0.200 |
Why?
|
| Aorta | 2 | 2016 | 139 | 0.190 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 248 | 0.190 |
Why?
|
| Islets of Langerhans | 1 | 2003 | 79 | 0.190 |
Why?
|
| Transients and Migrants | 1 | 2016 | 304 | 0.190 |
Why?
|
| Pancreas | 1 | 2003 | 108 | 0.190 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2016 | 755 | 0.190 |
Why?
|
| Mice, Knockout | 6 | 2017 | 486 | 0.180 |
Why?
|
| Virus Internalization | 2 | 2020 | 7 | 0.180 |
Why?
|
| Enzyme Activation | 4 | 2019 | 148 | 0.180 |
Why?
|
| Sensitivity and Specificity | 2 | 2021 | 614 | 0.180 |
Why?
|
| Phenylephrine | 3 | 2017 | 35 | 0.170 |
Why?
|
| Rats, Sprague-Dawley | 12 | 2012 | 923 | 0.170 |
Why?
|
| Hypertrophy | 2 | 2014 | 36 | 0.170 |
Why?
|
| Endothelium, Vascular | 2 | 2013 | 163 | 0.170 |
Why?
|
| Ventricular Function, Left | 3 | 2014 | 287 | 0.170 |
Why?
|
| Gestational Age | 4 | 2019 | 134 | 0.170 |
Why?
|
| Reference Standards | 1 | 2021 | 34 | 0.170 |
Why?
|
| Specimen Handling | 1 | 2021 | 33 | 0.170 |
Why?
|
| Models, Animal | 3 | 2011 | 198 | 0.160 |
Why?
|
| Endothelial Cells | 2 | 2012 | 204 | 0.160 |
Why?
|
| Rats, Inbred SHR | 9 | 2011 | 36 | 0.160 |
Why?
|
| Biological Transport | 2 | 2017 | 76 | 0.160 |
Why?
|
| Hispanic Americans | 1 | 2016 | 948 | 0.160 |
Why?
|
| Nephrectomy | 2 | 2012 | 127 | 0.150 |
Why?
|
| Heart Failure, Diastolic | 2 | 2011 | 15 | 0.150 |
Why?
|
| Nitrates | 2 | 2012 | 29 | 0.150 |
Why?
|
| Whole-Body Irradiation | 2 | 2016 | 59 | 0.150 |
Why?
|
| Free Radical Scavengers | 1 | 2019 | 15 | 0.150 |
Why?
|
| Protein Transport | 2 | 2016 | 82 | 0.150 |
Why?
|
| Organophosphorus Compounds | 1 | 2019 | 36 | 0.150 |
Why?
|
| C-Reactive Protein | 2 | 2012 | 248 | 0.140 |
Why?
|
| Hydrolysis | 2 | 2016 | 42 | 0.140 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2015 | 73 | 0.140 |
Why?
|
| Glomerular Filtration Rate | 4 | 2018 | 315 | 0.140 |
Why?
|
| PPAR delta | 1 | 2018 | 3 | 0.140 |
Why?
|
| Hydrogen Sulfide | 1 | 2018 | 4 | 0.140 |
Why?
|
| Pregnancy, Animal | 2 | 2011 | 20 | 0.140 |
Why?
|
| Piperidines | 1 | 2019 | 141 | 0.140 |
Why?
|
| Immunoblotting | 2 | 2009 | 57 | 0.140 |
Why?
|
| Receptor, Bradykinin B1 | 1 | 2017 | 1 | 0.130 |
Why?
|
| Neutrophil Infiltration | 1 | 2017 | 13 | 0.130 |
Why?
|
| Amino Acid Substitution | 1 | 2017 | 41 | 0.130 |
Why?
|
| Kinetics | 3 | 2014 | 259 | 0.130 |
Why?
|
| Myocytes, Cardiac | 4 | 2011 | 97 | 0.130 |
Why?
|
| Chymases | 3 | 2013 | 8 | 0.130 |
Why?
|
| Risk Factors | 4 | 2019 | 4137 | 0.130 |
Why?
|
| Trachea | 1 | 2017 | 56 | 0.130 |
Why?
|
| Lipopolysaccharides | 1 | 2017 | 122 | 0.130 |
Why?
|
| Pneumonia | 1 | 2017 | 70 | 0.130 |
Why?
|
| Guanylate Cyclase | 1 | 2017 | 9 | 0.130 |
Why?
|
| Cell-Free System | 1 | 2017 | 16 | 0.130 |
Why?
|
| Analysis of Variance | 4 | 2011 | 508 | 0.130 |
Why?
|
| Sodium, Dietary | 3 | 2015 | 23 | 0.130 |
Why?
|
| Phosphorylation | 2 | 2014 | 264 | 0.130 |
Why?
|
| Mitochondrial Membranes | 1 | 2016 | 27 | 0.120 |
Why?
|
| Gamma Rays | 1 | 2016 | 25 | 0.120 |
Why?
|
| Overweight | 1 | 2018 | 289 | 0.120 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2016 | 38 | 0.120 |
Why?
|
| Early Diagnosis | 1 | 2016 | 62 | 0.120 |
Why?
|
| Trauma Severity Indices | 1 | 2016 | 50 | 0.120 |
Why?
|
| Kidney Medulla | 2 | 2006 | 29 | 0.120 |
Why?
|
| Florida | 1 | 2016 | 41 | 0.120 |
Why?
|
| Chorionic Villi | 1 | 2015 | 8 | 0.120 |
Why?
|
| Dual Specificity Phosphatase 1 | 2 | 2012 | 27 | 0.120 |
Why?
|
| Body Weight | 4 | 2012 | 343 | 0.120 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2016 | 123 | 0.110 |
Why?
|
| Organ Size | 3 | 2012 | 236 | 0.110 |
Why?
|
| Insulysin | 1 | 2015 | 6 | 0.110 |
Why?
|
| Rats, Inbred WKY | 6 | 2011 | 21 | 0.110 |
Why?
|
| Infant, Newborn | 4 | 2018 | 730 | 0.110 |
Why?
|
| Albumins | 1 | 2014 | 47 | 0.110 |
Why?
|
| Animals, Genetically Modified | 4 | 2008 | 69 | 0.110 |
Why?
|
| Mercury Compounds | 1 | 2014 | 2 | 0.110 |
Why?
|
| Chromatography, DEAE-Cellulose | 1 | 2014 | 5 | 0.110 |
Why?
|
| Neurotensin | 1 | 2014 | 4 | 0.110 |
Why?
|
| Heart Diseases | 1 | 2015 | 124 | 0.110 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2014 | 45 | 0.110 |
Why?
|
| Transforming Growth Factor beta | 1 | 2014 | 67 | 0.110 |
Why?
|
| Cattle | 1 | 2014 | 118 | 0.110 |
Why?
|
| Vascular Resistance | 2 | 2011 | 33 | 0.100 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2014 | 74 | 0.100 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2014 | 222 | 0.100 |
Why?
|
| Phenanthrolines | 1 | 2013 | 3 | 0.100 |
Why?
|
| p-Chloromercuribenzoic Acid | 1 | 2013 | 3 | 0.100 |
Why?
|
| Phenylmercuric Acetate | 1 | 2013 | 4 | 0.100 |
Why?
|
| Edetic Acid | 1 | 2013 | 9 | 0.100 |
Why?
|
| Receptors, Cell Surface | 1 | 2014 | 83 | 0.100 |
Why?
|
| Collagen | 2 | 2012 | 240 | 0.100 |
Why?
|
| Adolescent | 6 | 2018 | 3805 | 0.100 |
Why?
|
| Random Allocation | 5 | 2013 | 257 | 0.100 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2017 | 104 | 0.100 |
Why?
|
| Mothers | 1 | 2014 | 94 | 0.100 |
Why?
|
| Infant, Very Low Birth Weight | 3 | 2018 | 50 | 0.100 |
Why?
|
| Aminopeptidases | 1 | 2012 | 3 | 0.100 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 439 | 0.100 |
Why?
|
| Thiazepines | 2 | 2002 | 3 | 0.090 |
Why?
|
| Biopterin | 1 | 2012 | 3 | 0.090 |
Why?
|
| Endopeptidases | 1 | 2012 | 34 | 0.090 |
Why?
|
| Nitrites | 1 | 2012 | 22 | 0.090 |
Why?
|
| Ecotoxicology | 1 | 2012 | 1 | 0.090 |
Why?
|
| Podocytes | 1 | 2012 | 20 | 0.090 |
Why?
|
| Toxicity Tests | 1 | 2012 | 13 | 0.090 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2012 | 21 | 0.090 |
Why?
|
| Nanostructures | 1 | 2012 | 21 | 0.090 |
Why?
|
| Heart Failure | 1 | 2019 | 780 | 0.090 |
Why?
|
| Water-Electrolyte Balance | 1 | 2011 | 17 | 0.090 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2011 | 18 | 0.090 |
Why?
|
| Fetal Weight | 1 | 2011 | 7 | 0.090 |
Why?
|
| Antigens, CD | 1 | 2012 | 106 | 0.090 |
Why?
|
| Fetal Growth Retardation | 1 | 2011 | 34 | 0.090 |
Why?
|
| Membranes | 2 | 2008 | 12 | 0.090 |
Why?
|
| Mediodorsal Thalamic Nucleus | 1 | 2011 | 5 | 0.090 |
Why?
|
| Hydralazine | 1 | 2011 | 7 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 118 | 0.090 |
Why?
|
| Captopril | 1 | 2011 | 8 | 0.090 |
Why?
|
| Vasoconstrictor Agents | 2 | 2009 | 65 | 0.090 |
Why?
|
| Heart Atria | 1 | 2011 | 84 | 0.090 |
Why?
|
| Aged | 4 | 2016 | 11022 | 0.080 |
Why?
|
| Muscle Contraction | 1 | 2012 | 183 | 0.080 |
Why?
|
| Iodine Radioisotopes | 2 | 2011 | 22 | 0.080 |
Why?
|
| Endothelin-1 | 3 | 2010 | 23 | 0.080 |
Why?
|
| Radioligand Assay | 1 | 2010 | 26 | 0.080 |
Why?
|
| Epistaxis | 1 | 2010 | 1 | 0.080 |
Why?
|
| Moraxellaceae Infections | 1 | 2010 | 2 | 0.080 |
Why?
|
| Moraxella | 1 | 2010 | 2 | 0.080 |
Why?
|
| Homeostasis | 2 | 2019 | 137 | 0.080 |
Why?
|
| Macaca | 1 | 2010 | 30 | 0.080 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 103 | 0.080 |
Why?
|
| Catalase | 1 | 2010 | 16 | 0.080 |
Why?
|
| Pregnancy Complications | 1 | 2011 | 115 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2018 | 926 | 0.080 |
Why?
|
| Monkey Diseases | 1 | 2010 | 28 | 0.080 |
Why?
|
| PPAR gamma | 1 | 2010 | 55 | 0.080 |
Why?
|
| Women's Health | 1 | 2011 | 242 | 0.080 |
Why?
|
| Isoenzymes | 2 | 2007 | 72 | 0.080 |
Why?
|
| SARS Virus | 2 | 2009 | 7 | 0.080 |
Why?
|
| Severe Acute Respiratory Syndrome | 2 | 2009 | 10 | 0.080 |
Why?
|
| Ventricular Remodeling | 1 | 2009 | 69 | 0.080 |
Why?
|
| Cell Membrane | 2 | 2009 | 111 | 0.080 |
Why?
|
| Maleimides | 1 | 2009 | 8 | 0.080 |
Why?
|
| Crosses, Genetic | 2 | 2006 | 21 | 0.080 |
Why?
|
| Respiratory System | 1 | 2009 | 11 | 0.070 |
Why?
|
| Behavior, Animal | 1 | 2011 | 303 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2013 | 281 | 0.070 |
Why?
|
| Protein Kinase C | 1 | 2009 | 43 | 0.070 |
Why?
|
| Autoradiography | 1 | 2009 | 55 | 0.070 |
Why?
|
| Disease Progression | 2 | 2019 | 634 | 0.070 |
Why?
|
| Natriuresis | 1 | 2008 | 5 | 0.070 |
Why?
|
| Indoles | 1 | 2009 | 67 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 204 | 0.070 |
Why?
|
| Alcoholism | 1 | 2009 | 103 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 4 | 2017 | 842 | 0.070 |
Why?
|
| Immunoglobulin G | 1 | 2009 | 136 | 0.070 |
Why?
|
| Inflammation | 1 | 2012 | 557 | 0.070 |
Why?
|
| Uterus | 1 | 2009 | 106 | 0.070 |
Why?
|
| Aorta, Thoracic | 1 | 2009 | 87 | 0.070 |
Why?
|
| Hypotension | 2 | 2011 | 49 | 0.070 |
Why?
|
| Protein Binding | 1 | 2009 | 255 | 0.070 |
Why?
|
| Succinates | 1 | 2008 | 6 | 0.070 |
Why?
|
| Kidney Tubules | 1 | 2008 | 26 | 0.070 |
Why?
|
| North Carolina | 2 | 2018 | 1613 | 0.070 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2009 | 124 | 0.070 |
Why?
|
| Anxiety | 1 | 2009 | 206 | 0.070 |
Why?
|
| Sodium Chloride | 1 | 2008 | 26 | 0.070 |
Why?
|
| Cells, Cultured | 3 | 2017 | 889 | 0.070 |
Why?
|
| Stress, Psychological | 1 | 2009 | 233 | 0.070 |
Why?
|
| Cell Adhesion Molecules | 1 | 2007 | 44 | 0.070 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2007 | 19 | 0.060 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2007 | 86 | 0.060 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2007 | 87 | 0.060 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2006 | 20 | 0.060 |
Why?
|
| Insulin | 2 | 2011 | 394 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2019 | 42 | 0.060 |
Why?
|
| Models, Genetic | 1 | 2006 | 95 | 0.060 |
Why?
|
| Growth Hormone | 1 | 2006 | 15 | 0.060 |
Why?
|
| Heterozygote | 1 | 2006 | 66 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2007 | 268 | 0.060 |
Why?
|
| Gene Silencing | 1 | 2005 | 47 | 0.060 |
Why?
|
| Hypertension, Renovascular | 1 | 2005 | 18 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2008 | 633 | 0.060 |
Why?
|
| Serine Endopeptidases | 1 | 2005 | 22 | 0.060 |
Why?
|
| Viral Envelope Proteins | 1 | 2005 | 12 | 0.060 |
Why?
|
| RNA, Small Interfering | 1 | 2005 | 118 | 0.060 |
Why?
|
| Adult | 4 | 2021 | 10030 | 0.060 |
Why?
|
| Microinjections | 3 | 2011 | 39 | 0.060 |
Why?
|
| Astrocytes | 1 | 2005 | 64 | 0.060 |
Why?
|
| Hormone Replacement Therapy | 1 | 2006 | 96 | 0.060 |
Why?
|
| Body Mass Index | 2 | 2018 | 954 | 0.060 |
Why?
|
| Lung Diseases | 1 | 2005 | 51 | 0.060 |
Why?
|
| Membrane Glycoproteins | 1 | 2005 | 118 | 0.050 |
Why?
|
| Ischemia | 1 | 2005 | 119 | 0.050 |
Why?
|
| Diuresis | 1 | 2004 | 6 | 0.050 |
Why?
|
| Polyuria | 1 | 2004 | 5 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 1607 | 0.050 |
Why?
|
| Creatinine | 2 | 2018 | 206 | 0.050 |
Why?
|
| Organ Specificity | 1 | 2004 | 86 | 0.050 |
Why?
|
| Myocardial Contraction | 3 | 2011 | 66 | 0.050 |
Why?
|
| F2-Isoprostanes | 1 | 2003 | 20 | 0.050 |
Why?
|
| Prognosis | 2 | 2019 | 1606 | 0.050 |
Why?
|
| Free Radicals | 1 | 2003 | 10 | 0.050 |
Why?
|
| Cardiomyopathies | 1 | 2003 | 70 | 0.050 |
Why?
|
| Myocardial Ischemia | 1 | 2003 | 114 | 0.050 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2002 | 11 | 0.050 |
Why?
|
| Phenotype | 2 | 2017 | 657 | 0.050 |
Why?
|
| Gene Expression | 2 | 2013 | 363 | 0.050 |
Why?
|
| Drosophila Proteins | 1 | 2002 | 48 | 0.040 |
Why?
|
| Genotype | 2 | 2016 | 744 | 0.040 |
Why?
|
| Bacteroides | 1 | 2021 | 8 | 0.040 |
Why?
|
| Prevotella | 1 | 2021 | 8 | 0.040 |
Why?
|
| Lactobacillus | 1 | 2021 | 13 | 0.040 |
Why?
|
| Feces | 1 | 2021 | 43 | 0.040 |
Why?
|
| Animals, Newborn | 2 | 2012 | 143 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2009 | 1523 | 0.040 |
Why?
|
| Leptin | 2 | 2011 | 75 | 0.040 |
Why?
|
| Primates | 1 | 2021 | 130 | 0.040 |
Why?
|
| Corticotropin-Releasing Hormone | 2 | 2011 | 12 | 0.040 |
Why?
|
| Antioxidants | 2 | 2012 | 126 | 0.040 |
Why?
|
| Perfusion | 2 | 2011 | 78 | 0.040 |
Why?
|
| Potassium | 2 | 2010 | 40 | 0.040 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2019 | 5 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2019 | 107 | 0.040 |
Why?
|
| Vasoconstriction | 2 | 2009 | 46 | 0.040 |
Why?
|
| Diet | 1 | 2021 | 418 | 0.040 |
Why?
|
| Rats, Inbred F344 | 2 | 2011 | 153 | 0.040 |
Why?
|
| Hyperglycemia | 2 | 2010 | 88 | 0.040 |
Why?
|
| Blood Glucose | 2 | 2011 | 529 | 0.030 |
Why?
|
| Middle Aged | 3 | 2016 | 12726 | 0.030 |
Why?
|
| Chemokine CXCL5 | 1 | 2017 | 3 | 0.030 |
Why?
|
| Drinking | 2 | 2009 | 10 | 0.030 |
Why?
|
| Protein Stability | 1 | 2017 | 27 | 0.030 |
Why?
|
| Fetal Organ Maturity | 1 | 2016 | 7 | 0.030 |
Why?
|
| Swine, Miniature | 1 | 2016 | 6 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 2016 | 30 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2016 | 83 | 0.030 |
Why?
|
| Lipid Peroxidation | 1 | 2016 | 34 | 0.030 |
Why?
|
| Glycosaminoglycans | 1 | 2016 | 23 | 0.030 |
Why?
|
| Swine | 1 | 2016 | 233 | 0.030 |
Why?
|
| Pyrrolidonecarboxylic Acid | 1 | 2015 | 4 | 0.030 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2016 | 64 | 0.030 |
Why?
|
| Protein Precursors | 1 | 2015 | 27 | 0.030 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2015 | 19 | 0.030 |
Why?
|
| Tissue Culture Techniques | 1 | 2015 | 44 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2015 | 63 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2015 | 84 | 0.030 |
Why?
|
| Superoxide Dismutase | 1 | 2014 | 48 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 823 | 0.030 |
Why?
|
| Mast Cells | 1 | 2013 | 13 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2013 | 35 | 0.030 |
Why?
|
| Obesity | 1 | 2021 | 1246 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 2367 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2018 | 2463 | 0.020 |
Why?
|
| Cyclic N-Oxides | 1 | 2012 | 8 | 0.020 |
Why?
|
| Spin Labels | 1 | 2012 | 27 | 0.020 |
Why?
|
| Cerebrospinal Fluid | 1 | 2012 | 18 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2012 | 95 | 0.020 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2012 | 15 | 0.020 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2012 | 19 | 0.020 |
Why?
|
| Ion Channels | 1 | 2012 | 27 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2012 | 41 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2012 | 46 | 0.020 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2012 | 30 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 703 | 0.020 |
Why?
|
| Soil Microbiology | 1 | 2012 | 1 | 0.020 |
Why?
|
| Comet Assay | 1 | 2012 | 3 | 0.020 |
Why?
|
| Micronucleus Tests | 1 | 2012 | 4 | 0.020 |
Why?
|
| Fishes | 1 | 2012 | 8 | 0.020 |
Why?
|
| Injections | 1 | 2012 | 76 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 2012 | 66 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2012 | 43 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2012 | 22 | 0.020 |
Why?
|
| Biological Assay | 1 | 2012 | 19 | 0.020 |
Why?
|
| Metals | 1 | 2012 | 20 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2016 | 1910 | 0.020 |
Why?
|
| Particle Size | 1 | 2012 | 49 | 0.020 |
Why?
|
| Autonomic Nervous System | 1 | 2012 | 51 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2012 | 51 | 0.020 |
Why?
|
| Mitochondrial Proteins | 1 | 2012 | 77 | 0.020 |
Why?
|
| Postmenopause | 1 | 2014 | 461 | 0.020 |
Why?
|
| Dual-Specificity Phosphatases | 1 | 2011 | 5 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2014 | 417 | 0.020 |
Why?
|
| Animals, Suckling | 1 | 2011 | 4 | 0.020 |
Why?
|
| Sucking Behavior | 1 | 2011 | 4 | 0.020 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2011 | 23 | 0.020 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2011 | 20 | 0.020 |
Why?
|
| Vasopressins | 1 | 2011 | 16 | 0.020 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2011 | 32 | 0.020 |
Why?
|
| Reference Values | 1 | 2011 | 265 | 0.020 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2011 | 19 | 0.020 |
Why?
|
| Anesthesia | 1 | 2011 | 72 | 0.020 |
Why?
|
| Hydrocortisone | 1 | 2011 | 61 | 0.020 |
Why?
|
| Sequence Analysis | 1 | 2010 | 6 | 0.020 |
Why?
|
| Nasopharynx | 1 | 2010 | 10 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 310 | 0.020 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2010 | 20 | 0.020 |
Why?
|
| Acetophenones | 1 | 2010 | 2 | 0.020 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating) | 1 | 2010 | 4 | 0.020 |
Why?
|
| Sexual Maturation | 1 | 2010 | 28 | 0.020 |
Why?
|
| Species Specificity | 1 | 2010 | 101 | 0.020 |
Why?
|
| Renal Blood Flow, Effective | 1 | 2010 | 1 | 0.020 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2010 | 6 | 0.020 |
Why?
|
| Lithium | 1 | 2010 | 6 | 0.020 |
Why?
|
| Protein Kinase C-epsilon | 1 | 2009 | 5 | 0.020 |
Why?
|
| Base Sequence | 1 | 2010 | 265 | 0.020 |
Why?
|
| Serine Proteases | 1 | 2009 | 1 | 0.020 |
Why?
|
| Receptors, Leptin | 1 | 2009 | 6 | 0.020 |
Why?
|
| Arterioles | 1 | 2009 | 17 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 389 | 0.020 |
Why?
|
| Receptors, GABA-B | 1 | 2009 | 19 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2009 | 56 | 0.020 |
Why?
|
| Cytokines | 1 | 2011 | 269 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 168 | 0.020 |
Why?
|
| Echocardiography | 1 | 2010 | 202 | 0.020 |
Why?
|
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2009 | 11 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 2009 | 23 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2009 | 15 | 0.020 |
Why?
|
| Cell Polarity | 1 | 2009 | 17 | 0.020 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2009 | 9 | 0.020 |
Why?
|
| Solubility | 1 | 2009 | 43 | 0.020 |
Why?
|
| Echocardiography, Doppler | 1 | 2009 | 47 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 2009 | 49 | 0.020 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2009 | 83 | 0.020 |
Why?
|
| Amygdala | 1 | 2009 | 64 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2009 | 118 | 0.020 |
Why?
|
| Renal Plasma Flow, Effective | 1 | 2008 | 1 | 0.020 |
Why?
|
| Heart Ventricles | 1 | 2010 | 155 | 0.020 |
Why?
|
| Diabetic Angiopathies | 1 | 2009 | 153 | 0.020 |
Why?
|
| Urodynamics | 1 | 2009 | 88 | 0.020 |
Why?
|
| Synaptic Transmission | 1 | 2009 | 125 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2008 | 110 | 0.020 |
Why?
|
| Eating | 1 | 2009 | 81 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2009 | 207 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 306 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 318 | 0.020 |
Why?
|
| Young Adult | 1 | 2015 | 2831 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2008 | 20 | 0.020 |
Why?
|
| Renal Circulation | 1 | 2007 | 13 | 0.020 |
Why?
|
| Ethanol | 1 | 2009 | 198 | 0.020 |
Why?
|
| Biphenyl Compounds | 1 | 2007 | 21 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 2007 | 17 | 0.020 |
Why?
|
| Superoxides | 1 | 2007 | 24 | 0.020 |
Why?
|
| Half-Life | 1 | 2007 | 25 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2007 | 71 | 0.020 |
Why?
|
| Lateral Ventricles | 1 | 2005 | 2 | 0.010 |
Why?
|
| Subfornical Organ | 1 | 2005 | 4 | 0.010 |
Why?
|
| Injections, Intraventricular | 1 | 2005 | 18 | 0.010 |
Why?
|
| Computer Systems | 1 | 2005 | 15 | 0.010 |
Why?
|
| Rats, Inbred BN | 1 | 2006 | 31 | 0.010 |
Why?
|
| Valine | 1 | 2005 | 14 | 0.010 |
Why?
|
| Cerebellum | 1 | 2005 | 27 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2005 | 69 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2005 | 127 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2011 | 4157 | 0.010 |
Why?
|
| Ligation | 1 | 2003 | 65 | 0.010 |
Why?
|
| Immune Sera | 1 | 2003 | 7 | 0.010 |
Why?
|
| Radiation Hybrid Mapping | 1 | 2002 | 4 | 0.010 |
Why?
|
| X Chromosome | 1 | 2002 | 27 | 0.010 |
Why?
|
| Metalloendopeptidases | 1 | 2002 | 12 | 0.010 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2002 | 47 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2002 | 77 | 0.010 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2002 | 30 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2002 | 70 | 0.010 |
Why?
|
| Drosophila melanogaster | 1 | 2002 | 43 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2002 | 597 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2002 | 3623 | 0.010 |
Why?
|